Turkmenistan
Tuberculosis profile
Population  2013 5.2 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (1.1–1.5) 25 (22–28)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 5.4 (2.5–9.4) 103 (47–180)
Incidence  (includes HIV+TB) 3.8 (3.1–4.6) 72 (59–87)
Incidence (HIV+TB only)        
Case detection, all forms (%) 80 (67–99)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.8 (1.1–9.5) 18 (11–28)
MDR-TB cases among notified pulmonary
TB cases
85 (25–210) 170 (100–250)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 220   272
Pulmonary, clinically diagnosed 1 028    
Extrapulmonary 526    
       
Total new and relapse 3 046    
Previously treated, excluding relapses 629    
Total cases notified 3 675    
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     81
Patients started on MDR-TB treatment     81
TB/HIV 2013 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 84
Previously treated cases registered in 2012 63
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 2.9
Drug susceptibility testing (per 5 million population) 2.9
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-06 Data: www.who.int/tb/data